This month's journal reports two studies using the combination of irinotecan and cisplatin in advanced non-small-cell lung cancer. The first is a phase II study that achieves a high response rate of 54%, with 33% of patients alive at 1 year (Masuda et al, 1998) . The second is a phase I dose-finding study of the same combination but given with concomitant radiotherapy in locally advanced disease. The initial doses chosen were of the order of 40% of the usual irinotecan weekly dose with 60 mg m-2 cisplatin. This chemoradiotherapy combination was not tolerated because of a number of toxicities, but in particular leucopenia. The study was stopped early but even at these low doses, a response rate of 67% was obtained (Yokoyama et al, 1998) . This has important implications for the use of irinotecan with radiotherapy in both lung and bowel cancer (Yokoyama et al, 1998) .
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Where do we take these new treatments and how do we make progress in the treatment of non-small-cell lung cancer? We now have five new drugs with activity in non-small-cell lung cancer and all of them priced in the range of between 6 and 30 times the cost of any of our previous regimens. This compounds the problem in non-small-cell lung cancer when the last new drug in the late 1980s, vinorelbine, has yet to be tested or accepted as standard treatment in this country. Currently, drug budgets are stretched to meet the increasing expenditure with our current 'cheap' regimens, never mind addressing new expensive treatments. It is a shame that we have come to the point when new treatments are not being hailed into clinical trials with enthusiasm and optimism, as currently there are no prospects that these new agents, if better, can then become standard treatments.
Gemcitabine, the taxanes (paclitaxel, docetaxel), the topoisomerase I inhibitors (irinotecan, topotecan) and vinorelbine all have significant single-agent activity with response rates of at least 20% and encouraging survival data with acceptable toxicities (Table 1) . There have now been numerous phase II studies investigating these agents in combination with platinum compounds, including the two in this issue. They have shown promising activity with relatively high response rates and 1-year survivals of 40% or more (Table 2) . However, although promising, these phase II studies must be viewed with caution, and judgment must be reserved until the results of phase III randomized studies comparing these combinations to standard treatments become available.
The commonest (standard) treatments for non-small-cell lung cancer in this country are cisplatin based, usually MVP (mitomycin, vinblastine and cisplatin) or MIC (mitomycin, ifosfamide and cisplatin), with cisplatin used at a dose of around 50 mg m-2. This differs to the USA where the cisplatin dose is usually higher and the combinations most frequently used are etoposide/cisplatin and vinblastine/cisplatin. The only randomized study comparing MIC, MVP (both using higher-dose cisplatin) and etoposide/cisplatin resulted in significant response and survival advantage for both three-drug regimens (Crino et al, 1995) . The use of higher cisplatin doses was based on one small randomized trial that demonstrated longer duration of response and a survival advantage for responders in the higher dose arm, but no overall survival results were reported (Gralla et al, 1981) . However, three subsequent larger randomized studies have failed to show advantage for the higher cisplatin doses, and toxicity was considerably worse (Klastersky et al, 1986; Gandara, 1993; Felip et al, 1997) .
The first randomized study using new agents compared vinorelbine/cisplatin to vindesine/cisplatin to vinorelbine alone in 612 patients. The vinorelbine/cisplatin combination resulted in a significantly superior response rate (30% vs 19% vs 14%), survival (median survival in weeks 40 vs 32 vs 31) and 1-year survival (35% vs 27% vs 30%) (Le Chevalier et al, 1996) . This study changed practice in the USA where vinorelbine/cisplatin is now standard therapy. Two more recent randomized studies comparing vinorelbine/cisplatin with either cisplatin alone or vinorelbine alone have further established the superiority of this combination (Gil Deza et al, 1996; Wozniak et al, 1996) .
The first of the studies using paclitaxel (Taxol) in combination with Cisplatin are now appearing. The ECOG study compared two doses of paclitaxel (250 and 135 mg m-2) with cisplatin to etoposide/cisplatin . Both paclitaxel/cisplatin doses resulted in similar response rates that were higher than the etoposide/cisplatin arm (27.7% vs 25.3% vs 12.4%). Hence, the two paclitaxel/cisplatin arms were combined for the survival analysis. The median survival was extended by about 2 months (9.8 vs 7.7 months, P = 0.048) in the paclitaxel/cisplatin arms, with an improvement in the 1-year survival (38.5% vs 31.6%). The EORTC have carried out a similar study, again comparing cisplatin and paclitaxel (175 mg m-2) against their standard regimen of cisplatin and teniposide. Again, the response rate for the pacilitaxel combination was higher (44% vs 30%), but median survival was similar in both arms (9.4 vs 9.7 months) (Giaccone et al, 1997) .
The third new agent to reach preliminary analysis in randomized trials is gemcitabine. A recently reported Taiwanese trial compared gemcitabine alone to etoposide/cisplatin. The response rate and survival were similar in both arms but the toxicity profile and inpatient days were markedly better in the gemcitabine arm (Perng et al, 1997) . This indicates that gemcitabine is a very well tolerated agent that would be suitable for palliative treatment of even elderly and frail patients. Finally, a Spanish study has compared gemcitabine/cisplatin to etoposide/cisplatin. This study (Fukuoka,1997) aNumber of trials in parentheses. Belani, 1997) aNumber of trials in parentheses. These randomized trials can be interpreted in a number of ways. All of these new regimens have higher response rates than our standard treatments and therefore the implication is that, if cytoreduction before surgery can result in cure, then greater cytoreduction will result in further cure. However, the first part of the hypothesis has yet to be proved conclusively, despite the encouraging results of two small randomized neoadjuvant studies (Rosell et al, 1994; Roth et al, 1994) . The results of larger studies are keenly awaited before this approach can become standard. Furthermore, care must be taken when introducing these new agents with concomitant radiotherapy, as demonstrated in this month's journal (Yokoyama et al, 1998) .
In the palliative setting, these new combinations may offer improved response rates and perhaps a modest prolongation of progression-free survival. Thus, palliative treatment needs to be assessed comparing data on rate and duration of symptom improvement, quality of life and economic analysis. The effect on overall survival is likely to be small, and none of these current trials have been powered to show small survival benefits (5% improvement over current treatments would require about 1000 patients in each trial). These issues will be debated fiercely from British Journal of Cancer (1998) 78(2), [159] [160] [161] [162] either side of the purchaser/provider standpoint before any new regimens will be accepted for either trials or treatments.
From the UK point of view, we want to know whether these treatments are better than our standard regimens. To carry out these trials, we will have to recruit about 1000 patients to improve on our current regimens (MVP and MIC). Currently, the market for these new agents is small in the UK compared with the market world-wide. It is therefore unlikely that the major pharmaceutical companies will fund these initiatives unless there is a suggestion that, if the new treatments prove better, they will become widely used and available. Currently, we are not able to fund these trials from drug budgets. It would appear that the whole system needs major overhauling with dissection of each part of the pathway leading to the introduction of new drugs.
Why are these new drugs so expensive? The reason is multifactorial. Firstly, these drugs appear to be expensive because, in the past 15 years, there have been few new drugs in oncology and therefore there has been no expansion in drug expenditure. Currently, only 1% of the current drug budget in the NHS has been spent on cytotoxic drugs. To catch up with this shortfall would take a major influx of cash. In addition, we have now found situations in which more patients require treatment with our old drugs; for example, patients with colon cancer now require adjuvant treatment with 5-fluorouracil (5-FU) and folinic acid (IMPACT, 1995) , and patients with node-negative breast cancer now require adjuvant treatment with CMF (Fisher et al, 1997) . However, the root of the problem is that new technology is expensive and drug development costs are now major. To develop one of the new taxoids has taken in the region of £260 million over a 10-year period, with investment purely by a pharmaceutical company. This leaves only about 5 years of licence remaining before the drug goes off patent, in other words 5 years to recoup the costs, make a profit and fund further development. Profits have to be made quickly as the fear is that when a drug comes off patent, competitor compounds will be introduced and the prices will fall. However, this has not always happened. For example, carboplatin is still one of our most expensive drugs, despite the introduction of a generic competitor. The same can be said for the price of anthracyclines, which, if anything, have increased over recent years.
These issues can be confounded by human factors, such as the influences of doctors and patients. Patients in the terminal phase of their disease have sometimes unreal expectations as to what can be achieved, often stimulated by media exaggeration of the facts. However, if these expensive new agent combinations result in genuine improvements in both palliation in the advanced setting and cure, in the neoadjuvant or the adjuvant setting, then long-term solutions must be found. Furthermore, the potential for litigation may loom if our cheap current therapies are shown to be substandard. These are difficult problems to resolve and will require innovative approaches to come up with a long-term solution. These solutions must set in place systems that will be robust enough to cope with the next 20 years.
The one thing that we have to offer in this country is good quality research, which produces data that are reputable and that are taken up widely and internationally. This is perhaps one of the things that we should exploit. We propose that the whole system of introducing new drugs should be re-examined and a system evolved in which the development of new drugs becomes an NHS research and development priority, with the handling of phase I, II and III trials carried out at an NHS level, with no cost to the pharmaceutical companies. This would immediately at least halve the cost of drug development and therefore have a follow-on effect on the price that new drugs are placed at in the market. A system of loyalty could be evolved that would take the nervousness out of developers and take away the fear of competitors. This would guarantee loyalty over a period of 10-15 years with one product. In return for all this, the NHS should be guaranteed a calculated percentage of the pharmaceutical companies' world sales/profits for this agent. This of course may threaten the major pharmaceutical companies but should be seen in the light of pharmaceutical companies and the NHS working hand-in-hand to our mutual benefit. At the same time as implicated in the British Medical Journal recently (Maynard and Bloor, 1997) , the whole drugpricing process needs to be reviewed to make sure that these agents are being introduced at a fair price. In addition, national systems need to be put in place with a national formula, based on consensus and fairness so that there is no unequal distribution of therapies and thus no fear of litigation. It is time for doctors to take responsibility so that systems can be devised, because, if we do not, there is only a limited number of solutions; these would take the form of increased taxation, introduction of a fee per item or the development of insurance policies to cover serious illness or any illness requiring high spending.
